Bcl-2 antisense therapy in B-cell malignant proliferative disorders

被引：10

作者：

Chanan-Khan A. ^{[1
]}

Czuczman M.S. ^{[1
]}

机构：

[1] Department of Medicine, Lymphoma and Myeloma Section, Roswell Park Cancer Institute, Buffalo, NY 14263, Elm and Carlton Streets

来源：

Current Treatment Options in Oncology | 2004年 / 5卷 / 4期

关键词：

Multiple Myeloma; Chronic Lymphocytic Leukemia; Thalidomide; Bortezomib; Mantle Cell Lymphoma;

D O I：

10.1007/s11864-004-0017-3

中图分类号：

学科分类号：

摘要：

Overexpression of Bcl-2 oncogene has been clinically associated with an aggressive clinical course, chemotherapy and radiotherapy resistance, and poor survival in patients with malignant B-cell disorders. Patients with relapsed or refractory chronic lymphocytic leukemia, multiple myeloma, or non-Hodgkin's lymphoma have limited therapeutic options. Preclinical and early clinical data have shown that Bcl-2 oncoprotein can be decreased by Bcl-2 antisense therapy. Also, downregulation of Bcl-2 protein can result in reversal of chemotherapy resistance and improved antitumor activity of biologic agents. Various clinical trials are evaluating the role of targeting Bcl-2 as a mechanism to enhance the antitumor potential of chemotherapy and immunotherapy. Early results from these clinical studies are encouraging and confirm the proof of principle for antisense therapy. As current data mature, these trials will hopefully validate preliminary results and establish Bcl-2 antisense as an important addition to the current armamentarium used in the treatment of patients with B-cell neoplasms. Copyright © 2004 by Current Science Inc.

引用

页码：261 / 267

页数：6

共 30 条

[11]

18) and bcl-2 gene expression in follicular small cleaved cell lymphoma and diffuse large cell lymphoma, Clin. Invest. Med., 20, pp. 364-370, (1997)

[12]

Ramanarayanan J., Chanan-Khan A., Czuczman M.S., Genasense Targeting Bcl-2 Protein Expression Enhances the Biological Anti-tumor Activity of Rituximab Against Non-Hodgkins (NHL) Cell Lines and Lymphoma Xerografts, (2003)

[13]

van de Donk N.W., Kamphuis M.M., van Dijk M., Et al., Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein, Leukemia, 17, pp. 211-219, (2003)

[14]

Lebedeva I., Stein C.A., Antisense oligonucleotides: Promise and reality, Annu. Rev. Pharmacol. Toxicol., 41, pp. 403-419, (2001)

[15]

Liu Q., Gazitt Y., Potentiation of dexamethasone-, paclitaxel-, and Ad-p53-induced apoptosis by Bcl-2 antisense oligodeoxynucleotides in drug-resistant multiple myeloma cells, Blood, 101, pp. 4105-4114, (2003)

[16]

Zhang Y., Shen W.L., Bcl-2 antisense oligodeoxynucleotide increases the sensitivity of leukemic cells to arsenic trioxide, Cell Biol. Int., 27, pp. 953-958, (2003)

[17]

Zhang Y., Lei X.Y., Effect of bcl-2 antisense oligodeoxynucleotides on drug sensitivity of leukemic cells, Hematol. J., 4, pp. 187-197, (2003)

[18]

Auer R., Corbo M., Bcl-2 antisense (Genasense) induces apoptosis and potentiates activity of both cytotoxic chemotherapy and rituximab in primary CLL cells, Blood, 98, SUPPL. 1, (2001)

[19]

Pepper C., Hooper K., Thomas A., Et al., Bcl-2 antisense oligonucleotides enhance the cytotoxicity of chlorambucil in B-cell chronic lymphocytic leukaemia cells, Leuk. Lymphoma, 42, pp. 491-498, (2001)

[20]

van de Donk N.W., G3139, a Bcl-2 Antisense Oligodeoxynucleotide, Induces Clinical Responses in VAD-refractory Myeloma, (2003)

← 1 2 3 →